Overview

Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2

Status:
Completed

Trial end date:
2006-12-01

Target enrollment:

Participant gender:

Summary

Randomized comparison of standard induction treatment with daunorubicin for 3 days and Idarubicin for 3 or 4 days in adult AML patients between 50 and 70 years. Study of maintenance treatment with IL2

Phase:

Phase 3

Details

Lead Sponsor:

Acute Leukemia French Association

Collaborator:

Assistance Publique - Hôpitaux de Paris

Treatments:

Cytarabine
Daunorubicin
Idarubicin